A New Way to Identify Patients likely to have Multiple Sclerosis

Diagnosing Multiple Sclerosis (MS) can be very difficult and time consuming,
sometimes taking months to years to receive a diagnosis.
Initially, physicians need to exclude other diseases that have similar symptoms. In addition, MRI examinations are not always clear and clinical symptoms are often inconclusive. These factors make diagnosing MS a complex and sometimes lengthy process, which can be very frustrating for individuals and physicians.
In order to help patients and physicians identify patients with a high probability of having MS, Glycominds has introduced the gMS Dx test, a new blood test for MS biomarkers. This revolutionary test helps physicians identify which patients that have had a first neurological event and a positive MRI are likely to develop MS.

Why use the gMS^®Dx test?

• NEW - First blood based biomarker test validated for MS
• POWERFUL - High positive predictive value for identifying patients likely to have MS after the first neurological event
• The gMS^®Dx test differentiates MS from other neurological diseases
• SIMPLE - Easy, non-invasive test, that complements MRI